{"contentid": 488708, "importid": NaN, "name": "South Korean approval and production deal for Moderna\u00e2\u0080\u0099s COVID-19 vaccine", "introduction": "Last Saturday, US biotech Moderna  announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved the company\u00e2\u0080\u0099s application for conditional marketing authorization for its mRNA vaccine against COVID-19.", "content": "<p>Last Saturday, US biotech Moderna (Nasdaq: MRNA) announced that the Ministry of Food and Drug Safety of South Korea (MFDS) has approved the company&rsquo;s application for conditional marketing authorization for its mRNA vaccine against COVID-19.</p>\n<p>GC Pharma in South Korea is the company&rsquo;s marketing authorization holder and distributor of Moderna&rsquo;s COVID-19 vaccine for the South Korea.</p>\n<p>The approval is based on the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase III clinical study <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.modernatx.com%2Fnews-releases%2Fnews-release-details%2Fmoderna-announces-primary-efficacy-analysis-phase-3-cove-study&amp;esheet=52433711&amp;newsitemid=20210521005307&amp;lan=en-US&amp;anchor=announced&amp;index=2&amp;md5=c4efb3777e0693876aeb3b98a2aeaec9\">announced</a> on November 30, 2020. South Korea has secured access to 40 million doses of COVID-19 Vaccine Moderna.</p>\n<h2><strong>Deal with Samsung Biologics</strong></h2>\n<p>Following swiftly on that news, Moderna revealed a manufacturing services and supply agreement under which Korea&rsquo;s Samsung Biologics (KRX: 207940.KS) will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna&rsquo;s COVID-19 vaccine.</p>\n<p>Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics&rsquo; facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna&rsquo;s COVID-19 vaccine intended for the supply of markets outside of the USA starting in the third quarter of 2021.</p>\n<p>&ldquo;This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,&rdquo; said John Rim, chief executive of Samsung Biologics. &ldquo;Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021,&rdquo; he added.</p>\n<h2><strong>Exploring collaboration with government</strong></h2>\n<p>Additionally, Moderna announced two Memoranda of Understanding (MoU) with the government of South Korea: one MoU with the Korea National Institute of Health (KNIH), an agency of the Korea Centers for Disease Control and Prevention Agency (KDCA) for a new collaboration on mRNA vaccine research in South Korea; and an additional MoU with the Ministry of Trade, Industry and Energy of the Republic of Korea (MOTIE), the Ministry of Health and Welfare of the Republic of Korea (MOHW) to explore local manufacturing opportunities for mRNA vaccines in South Korea.</p>\n<p>With these MoUs, Moderna and the KNIH will explore areas of collaboration for scientific research on mRNA vaccines. The teams will engage in discussions regarding collaboration opportunities such as pre-clinical or clinical development of mRNA vaccine candidates against viruses that create a high burden of disease in South Korea. These MoUs may also facilitate discussions between Moderna and South Korea for a potential manufacturing facility for mRNA vaccines in South Korea.</p>", "date": "2021-05-24 10:21:00", "meta_title": "South Korean approval and production deal for Moderna\u00e2\u0080\u0099s COVID-19 vacci", "meta_keywords": "Moderna, COVID-19 vaccine, Approval, Conditional, South Korea, Manufacturing, Agreement, Samung Biologics, Government, MoU, Research, mRNA vaccines", "meta_description": "South Korean approval and production deal for Moderna\u00e2\u0080\u0099s COVID-19 vaccine", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-23 14:53:48", "updated": "2021-05-24 10:21:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/south-korean-approval-and-production-deal-for-moderna-s-covid-19-vaccine", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "moderna_big.jpg", "image2id": "moderna_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "COVID-19 vaccines", "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Asia Pacific, Coronavirus, Deals, Focus On, Production, Regulation, Research", "geography_tag": "South Korea, USA", "company_tag": "Moderna, Samsung BioLogics", "drug_tag": "COVID-19 Vaccine Moderna", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-24 10:21:00"}